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Abstract
Background: Although IgG oligoclonal bands (OCBs) in the cerebrospinal fluid (CSF) are a frequent phenomenon
in multiple sclerosis (MS) patients, their relationship with grey matter lesions, intrathecal/meningeal inflammation
and clinical evolution has not been clarified yet.
The aim of our study was to assess the relationship between the OCBs, the inflammatory/neurodegenerative CSF
profile at diagnosis, the cortical lesion load and the clinical evolution after 10 years.
Methods: This is a 10-year observational, cross-sectional study based on a combined MRI, cognitive and CSF
profiling of the examined patients.
Forty consecutive OCB-negative (OCB−) and 50 OCB-positive (OCB+) MS patients were included in this study. Both
groups had mean disease duration of 10 years and were age and gender matched. Each patient underwent neurological
and neuropsychological evaluation and 3-T MRI. Analysis of the presence and levels of 28 inflammatory mediators was
performed in the CSF obtained from 10 OCB− MS, 11 OCB+ MS and 10 patients with other neurological conditions.
Results: Increased number of CLs was found in OCB+ compared to OCB− patients (p < 0.0001), whereas no difference
was found in white matter lesion (WML) load (p = 0.36). The occurrence of OCB was also associated with increased
levels of neurofilament light chains and of several inflammatory mediators linked to B lymphocyte activity and
lymphoid-neogenesis (CXCL13, CXCL12, CXCL10, TNFSF13, TNFSF13B, IL6, IL10) and other pro-inflammatory molecules,
such as IFN-γ, TNF, MMP2, GM-CSF, osteopontin and sCD163. Finally, the occurrence of OCB was found associated with
poor prognosis, from both physical and cognitive points of view.
Conclusions: OCB at MS onset are associated with more severe GM pathology and with a more severe physical disability
and cognitive impairment after 10 years. Increased levels of cytokines linked to B cell activation, lymphoid-neogenesis,
and pro-inflammatory immune response in the CSF of OCB+ patients support the hypothesis of crucial role played by
compartmentalized, intrathecal B cell response in the pathogenesis of CLs and OCB production.
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Background
Multiple sclerosis (MS) is a chronic immune-mediated
disease of the central nervous system (CNS) charac-
terized by demyelination, neurodegeneration and
axonal/glial pathology. Persistent intrathecal inflam-
mation, demonstrated by the presence of oligoclonal
bands (OCBs) in the cerebrospinal fluid (CSF) [1, 2],
is one of the main hallmarks of MS in about 87.7%
of MS patients [3]. The early detection of OCB in the
disease course, together with the deposition of antibody,
activation of complement and demyelination [4, 5], sup-
ports the role for B cells in MS pathogenesis. Clonally ex-
panded populations of memory B and plasma cells have
been found in the perivascular spaces, in the meningeal
infiltrates, and in the CSF of patients with MS, even at the
disease onset.
B cells express a specific chemokine receptor profile
dependent upon their state of differentiation and ex-
ternal microenvironment. Several chemokines have
been shown to influence CNS B cell trafficking and
activity: CCL2, CCL3, CCL20, CXCL10, CXCL12 and
CXCL13 [6]. Among these factors, increased CSF
levels of CXCL13, one of the most important chemo-
kine regulating B cell migration and differentiation in
MS patients and EAE models [7–9], corroborate the
hypothesis that the abnormal B cell immune response
persists and becomes compartmentalized in the CNS.
Diffuse inflammation, sometimes accompanied by the
formation of ectopic tertiary lymphoid tissues (TLT),
and recently detected in the inflamed meninges of
post-mortem secondary progressive MS cases [10–12],
may represent the niches within cerebral sulci in
which the B cell response persists and plays its role
in disease exacerbation. Inflammation within the sub-
arachnoid space is suggested to be involved in the
creation of an intrathecal inflammatory milieu that,
through circulating CSF, baths the external adjacent
cortical grey matter (GM) and mediates neuronal and
glia pathological alterations [10, 11, 13]. As shown by
several studies, the consequent GM damage is strictly
correlated with the accumulation of physical and cog-
nitive disability, and with the evolution of the pro-
gressive phase of the disease [14–17]. In a previous
preliminary, cross-sectional study [18], we observed
an association between cortical lesions (CLs) and
OCB but no formal hypotheses about the origin of
such association were suggested.
The aim of the present study was to confirm the rela-
tionship between OCB expression, cortical damage and
the unfavourable clinical evolution and to test the
hypothesis that the presence of OCB and CLs might be
related to the intrathecal inflammation and to the pres-
ence of subarachnoid tertiary B cell lymphoid-like
structures.
Methods
Patients
All consecutive OCB− patients having a diagnosis of MS
according to the most recent MS diagnostic criteria [19]
and who consecutively underwent neurological examin-
ation at the MS Centre of Verona University Hospital,
between January and December 2014, were asked to par-
ticipate in this study. Among these 44 patients, 2 were
excluded since their diagnosis was not confirmed, 2 did
not agree to participate, and 40 were enrolled in this co-
hort study. The mean disease duration for these patients
was 10.5 ± 7.3 years. Among the 815 OCB+ patients who
underwent neurological examination in our MS centre
in the same period, an MS population sex, age and dis-
ease duration matched with OCB− population was ran-
domly pulled out by a homemade algorithm (flow chart
in Additional file 1). Steroid therapy during the 2 months
before the enrolment was an exclusion criterion. See
Table 1 for demographic and clinical characteristics of
the two populations studied. Furthermore, 10 age- and
gender-matched control patients, with other neuro-
logical conditions, have also been recruited. The study
was approved by the local ethic committee, and in-
formed consent was obtained from all patients.
Clinical information
Each patient was assessed by means of the Expanded
Disability Status Scale (EDSS) [20] at the time of inclu-
sion in the study. Previous EDSS scores were retrospect-
ively acquired from the clinical records of each patient.
Data about previous and actual disease-modifying ther-
apies were collected. Patients were classified into four
categories, according to the type of drug administered
(Table 1).
Neuropsychological assessment
Neuropsychological assessment was performed at the
time of enrolment in the present study by means of the
brief repeatable battery (BRB) of neuropsychological
tests [21]—except the PASAT-2 subtest. The BRB is
composed by tests of verbal learning and delayed mem-
ory recall (Selective Reminding Test, SRT), visuo-spatial
learning and delayed memory recall (10/36 Spatial Recall
Test, SPART), auditory information processing speed,
working memory, attention, and calculation (Paced
Auditory Serial Addition Test, PASAT), visual informa-
tion processing speed and attention (Symbol Digit Mo-
dalities Test, SDMT), and semantic verbal fluency
(Word List Generation, WLG). Test scores were consid-
ered failed according to the cut-off scores (5th percent-
ile) derived from the Italian normative data [21].
Previous neuropsychological evaluations were excluded
from the analysis since the types of tests administered
were heterogeneous and then not comparable.
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The presence of depression was assessed by means of the
Beck Depression Inventory second edition (BDI-II) [22].
MS patients were classified into three groups: cognitively
normal (CN = no failed test of the BRB), mild cognitive
impairment (mCI = up to two failed tests), and severe cog-
nitive impairment (sCI = three or more failed tests).
CSF analysis
The CSF, collected at the time of diagnosis from all
the examined MS patients for diagnostic purposes,
was then available for protein analysis from 21 (11
OCB+ and 10 OCB−, strictly representative of the
two groups of examined MS patients) out of the 90
MS patients enrolled in the study and from 10 con-
trol patients (affected by other inflammatory neuro-
logical diseases, OIND). CSF sample collection and
preparation were performed more than 2 months
after the last relapse according to in-house guidelines
(used since 1994 by the bio-bank at the MS Centre of
Verona), which were in line with the Consensus
Guidelines for CSF and Blood Biobanking [23]. CSF,
obtained at the disease diagnosis, was centrifuged
soon after collection, and both the supernatant frac-
tion and the cell pellet were separately stored at
−80 °C until use. The presence of OCBs was per-
formed by using iso-electric focusing method and
blindly assessed by two independent examiners [24].
When possible, the assessment of the OCB in OCB−
MS patients was re-tested after second lumbar punc-
ture showing confirmation of OCB absence.
The presence and levels of 28 inflammatory media-
tors, including either the major pro-inflammatory me-
diators or molecules mainly related to the B cell
immune response (Table 2), were assessed using a com-
bination of immune-assay multiplex techniques based
on the Luminex technology (Table 2; Bio-Plex X200
System equipped with a magnetic workstation, BioRad,
Hercules, CA, USA). The CSF analysis was optimized
and performed by two independent investigators (RM
and SR), blinded with respect to the presence/absence
of OCB and to the clinical characteristics of the patient
and according to previously published procedures [25, 26].
All samples were run in duplicate and a number of
molecules have been measured in different immune-
assay platform in order to verify the reproducibility
and consistence of the results. The CSF level of each
protein detected during the analysis was normalized
to the protein concentration of each CSF sample
(measured by Bradford protocol).
The levels of neurofilament light chain (NF-L) in
CSF were measured using the Human NF-light ELISA
kit (MyBioSource, San Diego, CA, USA) according to
the manufacturer’s instructions. The monoclonal anti-
body was allowed to bind to the antigen for 90 min
at 37 °C and the unbound sample was washed away
followed by addition of a biotinylated human NF-L
Table 1 Clinical and MRI parameters at diagnosis and at the enrolment (whole population)
OCB+ OCB− Whole group p value
N (f/m) 50 (34/16) 40 (28/12) 90 (62/28) 0.511
Age (years) 42.5 ± 10.4 (19–67) 42.4 ± 11.2 (17–69) 42.5 ± 10.7 (17–69) 0.943
Years from onset to diagnosis 3.0 ± 5.1 (0–21) 2.6 ± 3.9 (0–17) 2.8 ± 4.6 (0–21) 0.356
Years from diagnosis to enrolment 7.8 ± 5.2 (0–20) 7.9 ± 6.4 (0–22) 7.9 ± 5.7 (0–22) 0.918
Years from onset to enrolment (disease duration) 10.8 ± 7.0 (1–31) 10.5 ± 7.3 (1–29) 10.7 ± 7.1 (1–31) 0.878
EDSS at diagnosis 1.5 (0–3.0) 1.0 (0–3.5) 1.5 (0–3.5) 0.645
EDSS at enrolment 2.8 (1.0–8.0) 1.5 (0–6.5) 2.0 (1.0–8.0) <0.0001
RRMS/SPMS at enrolment 35/15 36/4 71/19 0.018
Time to SPMS transition in months 123 ± 23 (98–187) 183 ± 13 (165–198) 136 ± 33 (98–198) <0.0001
Cognitive impairment CN/mCI/sCI 30/9/11 34/5/1 64/14/12 0.013
CL number at enrolment 6.1 ± 6.1 (0–24) 2.2 ± 2.8 (0–11) 4.4 ± 5.3 (0–24) <0.0001
WMLV at enrolment (cm3) 7.1 ± 3.6 (1.1–16.4) 6.5 ± 4.1 (1.3–18.1) 6.8 ± 4.0 (1.1–18.1) 0.258
Treatment until now
None 0 5 5 0.033
Only 1° linea 34 28 62
At least 2° linea 11 6 17
At least 3° linea 5 1 6
EDSS Expanded Disability Status Scale, RRMS relapsing-remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, CN cognitively normal, mCI mild
cognitive impairment, sCI severe cognitive impairment, CL cortical lesion, WML white matter lesion
Data are reported as mean ± standard deviation (range). For the EDSS, median and (range) are provided
a1° line drugs: IFN-beta, GA, azathioprine; 2° line drugs: fingolimod, natalizumab; 3° line drug: cyclophosphamide, mitoxantrone
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antibody at 37 °C for 1 h. The enzyme-conjugate
liquid was added after plate washed for 30 min at
37 °C and plate was then washed. The plate was
added with 3,3′,5,5′-tetrametilbenzidine (TMB) sub-
strate according to the manufacturer’s instructions
and read at λ450 nm within 10 min and the quantifi-
cation was carried out on VICTORTM X3 2030 Mul-
tilabel Plate Reader (Perkin Elmer, Walluf, Germany).
Intra-assay variability (coefficients of variation) sam-
ples were below 10%. Data obtained were normalized
for total protein concentration (mg/ml).
Image acquisition protocol
Each patient was scanned at enrolment using a 3.0-T
Philips Achieva MRI (Philips Medical Systems, Best, The
Netherlands), acquiring the following sequences:
Table 2 Methodological details of the examined inflammatory proteins in the CSF of MS patients by Bio-Plex immunoassay System
Detection limit (pg/ml) Intra-assay variation (%) Recovery percentage
range (90–110%)
BCA1/CXCL13 Chemokine (C-X-C motif) ligand 13 (CXCL13) or
B lymphocyte chemoattractant (BLC) or
B cell-attracting chemokine 1 (BCA-1)
0.42–6694 6.0 100
SDF1αβ/CXCL12 C-X-C motif chemokine 12 (CXCL12) or stromal
cell-derived factor 1 (SDF1)
12.73–160,858 5.4 104
6Ckine/CCL21 Chemokine (C-C motif) ligand 21 11.30–160,686 4.0 104
IP10/CXCL10 C-X-C motif chemokine 10 (CXCL10) or interferon
gamma-induced protein 10 (IP-10)
1.04–14,668 1.5 95
BAFF/TNFSF13B B cell activating factor (BAFF) or tumour necrosis
factor ligand superfamily member 13B (TNFSF13B)
70.19–197,936 6.3 100
APRIL/TNFSF13 A proliferation-inducing ligand (APRIL), or tumour
necrosis factor ligand superfamily member 13 (TNFSF13)
906.31–4,745,900 7.5 103
TWEAK/TNFSF12 TNF-related weak inducer of apoptosis (TWEAK) or tumour
necrosis factor ligand superfamily member 12
3.59–6346 4.4 106
LIGTH/TNFSF14 Tumour necrosis factor superfamily member 14 (TNFSF14) 1.92–4647 5.8 98
TNFα Tumour necrosis factor alpha 0.24–13,148 2.5 99
sTNFR1 Soluble- tumour necrosis factor-receptor 1 2.33–48,047 5.0 100
sTNFR2 Soluble- tumour necrosis factor-receptor 2 3.72–63,484 4.2 98
MIP3β/CCL19 Chemokine (C-C motif) ligand 19 (CCL19) or EBI1 ligand
chemokine (ELC) or macrophage inflammatory
protein-3-beta (MIP-3-beta)
3.08–49,150 2.8 103
MIG/CXCL9 Chemokine (C-X-C motif) ligand 9 (CXCL9) or monokine
induced by gamma interferon (MIG)
1.19–23,643 5.4 97
sCD163 Soluble-CD163 (Cluster of Differentiation 163) 0.38–10,497 6.0 102
GM-CSF Granulocyte-macrophage colony-stimulating factor
(GM-CSF) or colony-stimulating factor 2 (CSF2)
2.32–34,028 5.2 104
INFα2 Interferon alpha-2 1.24–19,334 5.3 99
INFβ Interferon beta 1.50–8727 6.0 100
INFγ Interferon gamma 1.50–2326 3.0 99
IL1β Interleukin-1 beta 0.15–2326 2.0 102
IL2 Interleukin-2 0.47–10,334 4.0 98
IL4 Interleukin-4 0.35–5258 6.0 100
IL6 Interleukin-6 0.68–57,162 3.0 99
IL8/CXCL8 Interleukin-8 (C-X-C motif) or chemokine
ligand 8, CXCL8)
11.56–8523 1.0 103
IL10 Interleukin-10 0.84–2997 3.0 98
OPN Osteopontin 123.64–286,066 7.3 100
MMP1 Matrix metallopeptidase 1 298.2–216,430 4.5 100
MMP2 Matrix metallopeptidase 2 90.63–2,109,030 3.3 104
MIF Macrophage migration inhibitor factor 8.25–456,461 2.6 103
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– 3D fluid attenuated inversion recovery (FLAIR) TR/
TE = 5500/292 ms, TI = 1650 ms, voxel dimension of
1 × 1 × 1 mm
– 3D double inversion recovery (DIR) TR/TE = 5500/
292 ms, TI1/TI2 = 525 ms/2530 ms voxel dimension
of 1 × 1 × 1 mm
– 3D T1 weighted fast field echo (FFE) TR/TE = 8.4/
3.7 ms, voxel dimension of 1 × 1 × 1 mm
Previous MRI examinations acquired at the time of
diagnosis (i.e. within 1 month from CSF collection) using
a 1.5-T Philips Achieva MRI scanner, were available for
35 OCB− and 48 OCB+ patients.
The following sets of images were acquired at a 1.5-T
scanner:
– 3D DIR: TR = 15,631 ms, TE = 25 ms, TI = 3400 ms,
delay = 325 ms, ETL = 17, 50 contiguous axial slices
with a thickness = 3 mm, matrix size = 130 × 256,
and field of view (FOV) = 250 × 200 mm
– 3D FLAIR: TR = 10,000 ms, TE = 120 ms, TI =
2500 ms, ETL = 23, 50 contiguous axial slices with a
thickness = 3.0 mm, matrix size = 172 × 288, and
FOV = 250 × 200 mm
– 3D FFE: 120 contiguous axial slices with the off-centre
positioned on zero, TR = 25 ms, TE = 4.6 ms, flip angle
= 30°, slice thickness = 1.2 mm, matrix size = 256 × 256,
and FOV= 250 × 250 mm
No major hardware upgrades were carried out on the
MRI scanners during the study.
Image analysis
All DIR images were assessed by consensus of two experi-
enced observers (MC and GF) blinded to patients’ iden-
tities and clinical data. Each CL was identified according to
the recent recommendations for CL scoring in patients
with MS [27]. All FLAIR images were assessed by consen-
sus of the same experienced observers, and the white mat-
ter lesion load was quantified. On FLAIR images, white
matter lesion volume was quantified after lesion identifica-
tion using a semi-automated local thresholding technique
based on Fuzzy C-mean algorithm, part of the Medical Im-
ages Processing Analysis and Visualization (MIPAV) soft-
ware (http://mipav.cit.nih.gov).
Statistics
Since EDSS scores were not normally distributed, the
Wilcoxon or Mann-Whitney test was used to compare
the two MS populations with respect to their EDSS
score at diagnosis and at enrolment.
Pearson chi-square was used to test the difference be-
tween the two MS groups in terms of categorical data
(i.e., female/male ratio; disease form: relapsing-remitting
MS vs secondary progressive MS) and cognitive status (a
ranked scale: CN vs mCI vs sCI). Univariate correlations
among continuous variables were assessed using the
Pearson correlation coefficient and those among discrete
variables with the Spearman rank correlation coefficient.
Differences among groups in continuous variables as
age, time from diagnosis to enrolment, time from onset
to diagnosis, and lesion load were assessed through ana-
lysis of variance (ANOVA). Mann-Whitney tests were
also used to test differences in terms of CSF protein
levels between OCB+ and OCB− MS patients. KEGG
pathway analysis was also used to perform unsupervised
pathway analysis on the CSF inflammatory mediators
levels. The Bonferroni correction was applied. All statis-
tical analyses were performed using SPSS v. 21 and R
(http://www.r-project.org).
Results
Clinical parameters
Despite the same mean age, disease duration, and EDSS
at the time of diagnosis (see Table 1), the OCB+ group
showed more severe disease evolution. Ten years after
the disease onset, the median EDSS score of OCB+ pa-
tients (2.8 [1.0–8.0]) was significantly higher than that of
OCB− patients (1.5 [0–6.5], p < 0.0001). The proportion
of patients who entered the SP phase was higher in OCB
+ (15/50, 30.0%) than in OCB− (4/40, 10.0%, p = 0.018)
and the time to reach the progressive phase was shorter
in OCB+ (mean 123 ± 23 months; range 98–187 months)
than in OCB− (mean 183 ± 13 months; range 165–
198 months; p < 0.0001) patients. The greater severity of
the pathological process in the OCB+ patients was also
confirmed by the need of administering a higher rate of
second- and third-line drug treatments compared to
OCB− patients (p = 0.033).
Finally, a significant difference was also observed be-
tween OCB+ and OCB− patients according to their clas-
sification in the three groups considering the number of
failed neuropsychological tests (p = 0.013): specifically,
30 OCB+ patients (60%) were classified as CN, 9 (18%)
were classified as mCI, and 11 (22%) were classified as
sCI; on the contrary, 34 OCB− patients (85%) were clas-
sified as CN, 5 (12.5%) were classified as mCI, and only
1 (2.5%) was classified as sCI (Table 1).
Imaging data
At the time of diagnosis, OCB+ patients showed 61.1%
higher number of CLs (1.8 ± 2.0 [0–5]) compared to OCB
− patients (1.1 ± 1.7 [0–6]; p = 0.041). CLs were detected
in 25/48 (52%) OCB+ and in 11/35 (31%) OCB− patients
(p = 0.075). No significant difference was observed in
terms of WM lesion load (p = 0.465) between the OCB+
(mean = 2.0 ± 0.9 cm3, range = 0.5–4.4 cm3) and OCB−
(mean = 1.6 ± 2.0 cm3, range = 1.0–5.9 cm3) patients.
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After 10 years of disease, OCB+ patients showed 2.7
times higher number of CLs (6.1 ± 6.05 [0–24]) com-
pared to OCB− patients (2.2 ± 2.8 [0–11]; p < 0.0001).
CLs were detected in 46/50 (92%) of OCB+ and in 23/40
(57%) of OCB− patients (p < 0.0001) Fig. 1.
As detected at the time of diagnosis, after 10 years no
significant difference was observed in terms of WM lesion
load (p = 0.258) between the OCB+ (mean = 7.1 ± 3.6 cm3,
range = 1.1–16.4 cm3) and OCB− (mean = 6.5 ± 4.1 cm3,
range = 1.3–18.1 cm3) patients.
CSF analysis (at the time of diagnosis)
Among the clinical CSF parameters, significant increased
in CSF cell count was found in OCB+ patients compared
to controls (p = 0.02); furthermore, increased IgG index
was detected in the CSF of OCB+ group compared to both
controls (p = 0.0075) and to the OCB− group (p = 0.039).
Significantly higher levels of NF-L were detected in the
CSF of OCB+ patients compared to both controls (fold
change = 2.260; p = 0.007) and OCB− patients (fold
change = 2.165; p = 0.024) (Fig. 2a). Among the 28 inflam-
matory molecules examined, 12 were significantly overex-
pressed (p < 0.05) in OCB+ compared to both controls
and OCB− MS patients (Fig. 2b, c): IL6, IL8, IL10,
CXCL13, CXCL12, TNF, APRIL, BAFF, IFNγ, MMP2,
osteopontin (OPN), sCD163. No difference in the CSF
levels of these molecules has been revealed in the OCB−
group compared to controls. Although a trend towards an
increase of few molecules was observed, such as MIF and
CCL19, no significant overexpression was found in the
CSF of OCB− patients. By using unsupervised pathway
analysis, the occurrence of OCB in the CSF at MS onset
was associated with the overexpression of molecules re-
lated to the B cell immune response, such as the lymphoid
chemokines CXCL13 (p < 0.001), CXCL12 (p < 0.001), fac-
tors related to B cell activation and differentiation such as
BAFF (p = 0.019), APRIL (p = 0.015), IL6 (p = 0.0005), and
IL10 (p = 0.035) (Fig. 2b) or to those with a B cell regula-
tory role, such as OPN (p = 0.019). Concomitant overex-
pression of the major pro-inflammatory molecules, such
as IFNγ (p < 0.001), TNF (p = 0.012), IL8 (p = 0.042),
MMP2 (p = 0.015) and the marker of activated monocytes,
sCD163 (p = 0.003), were found to be associated with the
presence of OCB (Fig. 2b, c).
In the OCB+ MS patients, CL load significantly corre-
lated with levels of several molecules linked to the B cell
immune response, such as CXCL13 (r = 0.922; p < 0.001),
CXCL12 (r = 0.678; p = 0.022), OPN (r = 0.692; p = 0.018),
IL6 (r = 0.628; p = 0.039), TWEAK (r = 0.629; p = 0.038)
(Fig. 3). EDSS scores positively correlated with the protein
levels of CXCL12 (r = 0.679; p = 0.022), GM-CSF (r = 0.626;
p = 0.039) and IL1beta (r = 0.625; p = 0.040) (Fig. 4).
Discussion
In this study we showed that a more inflammatory intra-
thecal profile and a more severe cortical demyelination
are usually associated to the occurrence of OCB at MS
diagnosis and to a more severe clinical evolution after
10 years of follow-up. To draw this conclusion, we eval-
uated the evolution of physical and cognitive disability,
the time to progressive phase of the disease and the
number of CLs in relapsing-remitting multiple sclerosis
(RRMS) patients with and without OCB, at diagnosis
and after about 10 years of disease duration. From the
Fig. 1 3D double inversion recovery images of three RRMS OCB+ patients (a–c) and three RRMS OCB− patients (d–f). OCB+ patients show both
white and grey matter demyelination (arrows) including insular lesions (arrows, c). OCB− patients do not show any grey matter lesion despite the
severe white matter demyelination especially in the periventricular region (arrowheads, d–f)
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clinical point of view, physical and cognitive results sug-
gest that the presence of OCB at diagnosis can be associ-
ated with a worse prognosis. In addition the presence of
OCB in the CSF of MS patients is linked to increased CSF
cell counts and IgG index, that could reflect the higher in-
flammatory condition of the CSF of the OCB+ group. In
particular, while the cell count significantly differs in OCB
+ patients only compared to controls, the significant in-
crease in IgG levels in OCB+ compared to both controls
and OCB− may demonstrate the preponderance of the
humoral response in OCB+ MS patients. In OCB+ group,
the number of patients who entered the progressive phase
of the disease was significantly higher, and the time to
reach the progressive phase was significantly shorter than
in OCB− patients group. Such differences of disease
course could be explained by the presence of higher intra-
thecal inflammation and by the consequent higher cortical
damage. Indeed, although the presence of CLs was not ex-
clusive of patients with OCB, we showed that patients
with OCB, despite the similar age, disease duration and
Fig. 2 Protein analysis of the presence and levels of neurofilament light chains (NF-L) and inflammatory mediators in CSF. a NF-L protein levels have
been analysed in the CSF of controls, OCB− and OCB+ MS patients by using ELISA assessment, showing significant increased levels in OCB+ MS patients
compared to both controls and OCB− MS patients. b Cluster analysis showing the level of expression of the 28 inflammatory mediators examined in
OCB− and OCB+ MS patients: the red rectangle outlines a cluster of molecules significantly overexpressed only in OCB+ MS patients. c Statistical
representation of the presence and levels of inflammatory mediators significantly overexpressed in OCB+ compared to controls and to OCB− MS
patients. (Statistical analysis performed by using Mann-Whitney test; p value *<0.05; **<0.01; ***<0.001)
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Fig. 3 Pearson correlation analysis between the CSF levels of overexpressed proteins and the number of cortical lesions detected by 3 T MRI in
the subgroup of the 21 MS patients. All the represented correlations involve molecules related to B cell chemo-attraction (CXCL13, CXCL12) and
activity (IL6, OPN, TWEAK). The r and p values are reported for each examined correlation in the correspondent graph
Fig 4 Pearson correlation analysis between the CSF levels of overexpressed proteins and the EDSS values of the subgroup of the 21 MS patients
at the follow-up. The r and p values are reported for each examined correlation in the correspondent graph
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WM lesion load, had a substantial increase of the CL load
compared to patients without OCB, already at the time of
diagnosis. Our hypothesis is that the presence of OCB
might be an epiphenomenon of the compartmentalized
intrathecal (meningeal) B cell response, which has been
suggested to be associated with increased subpial demye-
lination and neuronal damage, both hallmarks of more
rapidly progressive disease [12, 28–31]. While no differ-
ence in the levels of B cell-related CSF inflammatory me-
diators was found between controls and OCB− patients, it
can be not excluded that differences in others CSF media-
tors may occur.
To provide more supporting evidence, we assessed
the intrathecal CSF profile of a subgroup of patients
with and without OCB. Our results confirmed that
OCB+ patients have a greater intrathecal inflamma-
tory activity already at the diagnosis. Such intrathecal
inflammation was characterized by overexpression of
molecules related to B cell differentiation/activity, in-
flammatory immune response and monocyte activa-
tion compared to both control and OCB− groups.
Indeed, high levels of lymphoid chemokines CXCL13
and CXCL12, having a key role in the regulation of B
cell migration and compartmentalization within sec-
ondary lymphoid organs [9], IL6 and IL10, involved
in plasma blast differentiation/class switching as well
as B cell regulatory immune activity, and BAFF,
APRIL, and osteopontin, involved in the balance be-
tween activation, survival and apoptosis of B and T
cells [30], were observed in OCB+ MS patients only.
Our results confirm and extend previous observations
of high levels of CXCL13 and increased numbers of
naïve and memory B cells expressing its receptor,
CXCR5, in the CSF of MS patients with intrathecal
IgG synthesis and characterized by a more aggressive
disease course [31–35]. Moreover, by stratifying pa-
tients on the basis of the OCB presence at diagnosis,
we observed a direct correlation between high levels
of CXCL13 (and other B cell-related molecules), CL
load, and both long-term physical and cognitive dis-
ability. From the neurodegenerative point of view, the
elevated level of CXCL12 detected in OCB+ MS pa-
tients, together with the high levels of NF-L discov-
ered in the same MS patients, is in line with the high
level of GM damage as suggested by the high number
of CLs observed in OCB+ MS patients, suggesting a
higher degree of neuronal and axonal damage in this
subgroup of patients [36]. Indeed, in addition to its
role in the immune system, CXCL12, which is pro-
duced by activated astrocytes, can induce neuronal
apoptosis in certain conditions and promote survival
of neurons in others [37]. Metalloproteinase (MMP)-
2, that we also found overexpressed in the OCB+ MS
patients, could have a direct role in cortical tissue
damage by breakdown of extracellular matrix but could be
also able to convert CXCL12 into a neurotoxic form [32].
The increased expression of several inflammatory mole-
cules such as IFNγ, TNF, IL8, IL10, IL6, MMP2, and osteo-
pontin found in OCB+ MS patients indicate higher levels
of intrathecal inflammatory activity that may be directly
involved in the cortical tissue damage, as well as indirectly
by activation of resident glial cells. In particular, the high
levels of IFNγ and TNF in the CSF of OCB+ MS patients
with higher CL load is in agreement with the finding of in-
creased IFNγ and TNF gene and protein expression in
paired post-mortem meninges and CSF obtained from sec-
ondary progressive multiple sclerosis (SPMS) cases with
increased meningeal inflammation, cortical damage and
rapid disease progression [38]. Finally, the concurrent find-
ing in OCB+ MS patients of increased levels of sCD163,
that was proposed as possible informative marker of acti-
vated macrophages and disease activity [39–45], might
suggest that an elevated intracerebral lymphocytic and
macrophage activity is linked to more severe CL load and
disease severity.
The intrathecal B cell activity and severe cortical path-
ology observed in OCB+ MS patients is also consistent
with our previous studies demonstrating the presence of
abnormal inflammation and tertiary lymphoid-like organs,
rich in B-lymphocytes and plasma cells, in the meningeal
infiltrates in the subarachnoid space in SPMS and primary
progressive MS cases with a more rapid and severe disease
progression [10, 12, 46]. Such a relationship would confirm
our hypothesis that meningeal immune cell infiltrates may
represent niches for the perpetuation of plasma cell activ-
ity and, therefore, together with the presence of long-lived
plasma cells, of production sites of OCB immunoglobulins
and of inflammatory factors. These inflammatory factors
may diffuse across the glia-limitans and play a crucial role
in the subpial damage, inducing demyelination, neurode-
generation, and glia alteration mediating a more severe
and rapid progression [13, 38]. These events could occur
since the early phases of the disease as suggested by the
higher number of CLs observed in OCB+ patients since
disease diagnosis and by other studies demonstrating the
presence of increased meningeal inflammation [47] and
meningeal enhancement [48] associated with increase sub-
pial cortical demyelination in a subgroup of MS patients
characterized by early and rapid disease progression.
We are aware that our study is not without limitations:
first of all the limited number of the patients whose CSF
was examined does not allow to drive any definitive con-
clusion; in addition, the limited number of patients does
not allow further sub-analyses, stratifying the patients
according to other clinical parameters (e.g., comparison
between RRMS and SPMS forms of the OCB+ and OCB
− groups, comparison of the same treatment lines, com-
parison of different MS forms in the same OCB group).
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Moreover, although our MRI protocol was performed at
a 3-T scanner and included a double inversion recovery
sequence, a significant proportion of CLs could have es-
caped our detection. Finally, the retrospective nature of
the study could be considered a limitation. However, it
allowed us to choose patients whose diagnosis was con-
firmed by a very long clinical and radiological observation,
and permitted us to correlate, for the first time, long-term
clinical and radiological outcomes with the inflammatory
features of the CSF obtained at the diagnosis.
Conclusions
The present study confirms and extends our previous ob-
servation [18] of strong relationship between OCB and
CLs in MS and shows that after almost 10 years of disease
duration the number of CLs was about threefold higher in
OCB+ compared to OCB− patients, despite the same
WM lesion load both at diagnosis and at follow-up. Intra-
thecal inflammation, in particular linked to B cell immune
response, seems to be involved in the production of OCB
and in the pathogenesis of cortical damage in MS. Al-
though our data needs to be confirmed in different and
larger MS cohorts and by longer perspective follow-up,
we suggest that a well-defined pro-inflammatory CSF pro-
file is associated with early occurrence of OCB in the CSF,
with development of a more severe cortical pathology,
and with a worse clinical (physical and cognitive) progno-
sis. These results indicate that the evaluation of intrathecal
inflammation, combined with the assessment of GM le-
sion load at the time of diagnosis, might constitute a cru-
cial prognostic tool, which could be helpful in selecting
the most appropriate therapy.
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